Cabometyx (cabozantinib) is a brand-name oral tablet prescribed for certain types of cancer in adults and some children. The cost of the drug, with and without insurance, can depend on several ...

Exelixis is pursuing an additional approval for Cabometyx in neuroendocrine tumors. The U.S. FDA has assigned an action date ...

Stopping a cancer trial is either a very good, or very bad thing – and luckily for Ipsen the former was the case after a liver cancer trial of its Cabometyx pill was curtailed because of the ...

The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The commission granted a marketing authorisation for Cabometyx ...

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

Update 1:25pm: Adds Jefferies analyst comment. Exelixis (NASDAQ:EXEL) rose 5% as the patent trial over its Cabometyx drug ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil A ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib ...

Exelixis (NASDAQ:EXEL) has released additional phase 3 data on Cabometyx (cabozantinib) in individuals with pancreatic neuroendocrine tumors (pNET) and with advanced extra-pancreatic ...